Cue Biopharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
March 16, 2021 16:01 ET
|
Cue Biopharma, Inc.
Evaluated initial observations in CUE-101 Phase 1 monotherapy dose escalation clinical trial for treatment of human papilloma virus positive recurrent/metastatic head and neck squamous cell carcinoma...
Cue Biopharma to Present Corporate Overview and Clinical Progress at the Upcoming Oppenheimer 31st Annual Healthcare Conference
March 15, 2021 08:00 ET
|
Cue Biopharma, Inc.
CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to...
Cue Biopharma to Host Business Update Call and Webcast
March 09, 2021 08:00 ET
|
Cue Biopharma, Inc.
CAMBRIDGE, Mass., March 09, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to...
Cue Biopharma to Present at the Cowen 41st Annual Health Care Conference
March 01, 2021 08:00 ET
|
Cue Biopharma, Inc.
CAMBRIDGE, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to...
Cue Biopharma Enhances Scientific Advisory Board with Appointments of Immunology and Immunotherapy Experts Dr. Abul K. Abbas and Dr. Michael Kalos
February 25, 2021 08:00 ET
|
Cue Biopharma, Inc.
CAMBRIDGE, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to...
Cue Biopharma to Present at the 7th Annual Immuno-Oncology 360° Conference
February 22, 2021 08:00 ET
|
Cue Biopharma, Inc.
CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to...
Cue Biopharma Announces Appointment of Matteo Levisetti, M.D. as Senior Vice President of Clinical Development
February 17, 2021 08:00 ET
|
Cue Biopharma, Inc.
Appointment to strengthen clinical development capabilities with a strategic and visionary immunotherapy leader as Cue Biopharma advances its pipeline of drug development programs CAMBRIDGE, Mass.,...
Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 in Combination with KEYTRUDA® (pembrolizumab) as First-line Treatment for HPV+ Recurrent/Metastatic Head and Neck Cancer
February 08, 2021 08:00 ET
|
Cue Biopharma, Inc.
CAMBRIDGE, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to...
Cue Biopharma to Present at the Piper Sandler 32nd Annual Healthcare Conference
November 23, 2020 08:00 ET
|
Cue Biopharma, Inc.
CAMBRIDGE, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to...
Cue Biopharma Extends Research Collaboration for the Development of Immuno-STAT Biologics for the Treatment of Defined Autoimmune Diseases with Merck
November 19, 2020 08:00 ET
|
Cue Biopharma, Inc.
CAMBRIDGE, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively...